Publications
Extracellular Matrix Pharmacology Congress (June 2022)
ECM-derived Biomarkers in Drug Discovery: Are they ready to deliver? Poster – Darcey Black.
Drug discovery and development in idiopathic pulmonary fibrosis:
challenges and opportunities (Drug Discovery Today, Sept 2020)
A paper detailing the current treatments and clinical development landscape in IPF, as well as the new drugs in clinical trials and considerations for combination therapies. – Simon Cruwys, Peter Hein, Bob Humphries, Darcey Black. View paper.
The future R&D landscape in non-alcoholic steatohepatitis (NASH) (Feb 2019)
An article aiming to give Discovery Teams some guidance on navigating the maze of information available and some pointers to factors to consider in early research projects. – Darcey Black, Sarah Brockbank, Simon Cruwys, Kim Goldenstein, Peter Hein, Bob Humphries. View paper.ERS Internation al Congress, Paris (Sept 2018)
Scar-in-a-Jar, an in vitro screening tool for antifibrotics – J. Sand, N. Gudmann, S. Ronnow, S. Brockbank, S. Cruwys, M. Karsdal, D. Lemming
ERS Internation al Congress, Paris (Sept 2018)
Clinically validated markers of the extracellular matrix remodelling are altered by potential anti-fibrotic compounds in a human lung fibrosis ex vivo model – D.J. Lemming, J.M.B. Sand, C. Hesse, S. Konzok, K. Sewald, S. Ronnow, A. Braun, M. A. Karsdal, S. Brockbank, S. Cruwys
Aegean Fibrosis and Tissue Repair conference, Crete (June 2018)
Clinically validated markers of extracellular matrix remodelling are modulated by anti-fibrotic compounds in a human lung fibrosis ex vivo model – D.J. Lemming, J.M.B Sand, C. Hesse, S. Konzok, K. Sewald, S. Ronnow, A. Braun, M. A. Karsdal, S. Brockbank, S. Cruwys
Aegean Conference Crete (June 2018)
Development of multiple rodent models of non-alcoholic steatosis and steatohepatitis (NASH) – a profile of a rodent NASH-CRN score – Samuel J. Daniels, Diane J. Leeming, Maria F. Bruun, Sönke Detlefsen, Sara T. Hjuler, Morten A. Karsdal, Peter Hein, Sarah Brockbank, Simon Cruwys
Internation al Liver Conference (EASL), Paris (April 2018)
Evaluation of the rodent Octodon degus as a pre-clinical model of liver fibrosis – Sarah Brockbank, Patricia Cogram, Diane Julie Leeming, Sara Toftegaard Hjuler, Simon Cruwys
Global NASH meeting, London (Feb 2018)
Development of multiple Rodent models of non-alcoholic steatohepatitis – a biomarker profile – Samuel J. Daniels, Sofie Gydesen, Sara T. Hjuler, Diane J. Lemming, Kim Henriksen, Patricia Cogram, Mette E. Ronne, Morten A. Karsal, Peter Hein, Sarah Brockbank, Simon Cruwys
Global NASH meeting, London (Feb 2018)
Evaluation of compounds with claimed anti-fibrotic activity in an in vitro primary human stellate cell to myofibroblast transition assay – Mischa Vrouwe, Yasmin Habani, Niki van der Steenstraten, Alan Young, Simon Cruwys, Anne-Marie Zuurmond, Jamil Aarbiou, Sarah Brockbank, Jeroen DeGroot
17th Fraunhofer Meeting “MODELS OF LUNG DISEASE”
Neoepitope fragments of extracellular matrix as markers of pulmonary fibrosis: Insights into clinical and preclinical utilization for unfolding disease pathogenesis – Diane J Lemming
Fraunhofer (Jan 2017), invited presentation
A novel human fibroblast to myofibroblast transition assay as a tool for compound testing in IPF – Natasja Stæhr Gudmann, Jamil Aarbiou, Simon Cruwys, Sarah Brockbank, Alan Young, Diana Julie Leeming, Jeroen De Groot
Keystone (March 2017)
Quantitative Image Analysis of Fibrotic Lesion Progression in the Mouse Bleomycin Model of Pulmonary Fibrosis – A. Young, L. Sherry, M. Anderson P. Nath, J. Baily, Mary McElroy, S. Brockbank, S. Cruwys
Keystone (March 2017)
A comparison of compounds with claimed anti-fibrotic activity in two novel human primary cell based assays using IPF derived patient material – Mischa Vrouwe, Jamil Aarbiou, Diana Julie Leeming, Simon Cruwys, Natasja Stæhr Gudmann, Sarah Brockbank, Alan Young, Jeroen DeGroot
Keystone (March 2017)
Development of an LC-MS method for the selective detection of collagen types – Anne J. Kleinnijenhuis, Frederique L. van Holthoon, Aranne van Koppen, Sarah Brockbank, Simon Cruwys, Joline Attema, Roeland Hannemaaijer, Reinout Stoop
Experimental Biology (April 2017)
The Assessment of Clinically Relevant Extracellular Matrix Markers in a Bleomycin-Induced Mouse Model of Lung Fibrosis – Alan Young, Puneeta Nath, Diana Leeming, Morten Karsdal, Sarah Brockbank, David Riderand and Simon Cruwys
American Thoracic Society (May 2017)
Quantification of Differential Fibrotic Lesions by Image Analysis in the Mouse Bleomycin Model of Pulmonary Fibrosis – Lorcan Sherry, Mark Anderson, Alan Young, Puneeta Nath, James Baily, Mary C. McElroy, Sarah Brockbank, Simon Cruwys
American Thoracic Society (May 2017)
A Comparison Of Compounds With Claimed Anti-fibrotic Activity In A Novel Human Fibroblast To Myofibroblast Transition Assay Using IPF Derived Patient Material – Jamil Aarbiou, Diana J. Leeming, Simon Cruwys, Natasja S. Gudmann, Sarah Brockbank, Alan Young, Jeroen De Groot
European Respiratory Society Meeting (Sept 2017)
Modulation of collagen formation and crosslinking in the Scar-in-a-Jar model – Sand JMB, Leeming DJ, Genovese F, Karsdal MA, Simon Cruwys, Sarah Brockbank
In 2016 (Keystone, ATS, Aegean Fibrosis Meeting)
6 poster abstracts, 1 presentation